RAVCARE digital therapeutics technology employ objective and sensitive methods to assess behavioral characteristics, including facial expressions, vocal acoustics, speech patterns, movement patterns, and eye movements. These behavioral measures can be used to quantify clinically significant symptoms, such as emotional expressivity, voice prosody, speech valence, and tremor severity, among many others.
Facial Activity Biomarkers
Facial activity biomarkers encompass visually observable facial characteristics, including movements and configurations of facial muscles, which can convey emotional expressions and other information, such as pain.
Action unit presence and intensity values are used to measure presence and intensity of emotional expressions, given that combinations of different action units refer to individual emotions.
Overall expressivity is a measure of facial expressivity regardless of emotional state. All action unit values are combined to determine the overall expressivity of the face, typically useful for measurement of blunted affect or disruption of facial expression as a consequence of motor retardation.
Similar to emotion expressivity, pain expressivity is calculated using a combination of action units as defined in the Facial Action Coding System (FACS).
Verbal Acoustic Biomarkers
Verbal acoustics encompass the quantitative analysis of the acoustic features of a person’s voice.
Glottal-to-noise excitation ratio, is an indirect measure of breathiness, indicating whether a “given voice signal originates from vibrations in the vocal folds or from turbulent noise generated in the vocal tract.”
The jitter of an audio signal is the parameter of frequency variation from cycle to cycle, and is affected mainly by the lack of control over vocal cord vibration.
Whereas the previous section delved into the acoustic aspects of speech, this section explores the linguistic features of language.
Parts of speech simply describe aspects of the language used, such as usage of verbs, pronouns, adjectives, etc. along with other helpful measures such as the number of sentences spoken.
This refers to the emotional valence of the transcribed text based. This determination is based on pre-trained models. Positive values of sentiment indicate positive emotional valence, while negative values indicate negative emotional valence.
There are several terms for this measurement used across literature (sometimes also called diversity in vocabulary, etc.) Simply put, it quantifies how many unique words are used in speech, which can be a proxy to some clinical measurements.
Rate of speech is simply a measure of words spoken per given unit of time. We measure this in words spoken per minute.
This refers to the detection of movement in videos of individuals, primarily focusing on their head and facial movements. This analysis involves tracking and analyzing subtle changes in facial expressions, head movements, eye gaze, and blink behaviour, providing valuable insights into an individual’s emotions, intentions, and overall behavior.
Eye blinks are measured by first calculating a variable called eye aspect ratio (EAR).
Eye gaze directionality is another output variable that allows for measurements of eye gaze behavior.
Measurements of facial tremor are acquired by looking at movements in individual facial landmarks.
Vocal tremor is measured according to the methods commonly used to distinguish aspects of this biomarker
If you have general questions on digital therapeutics technology, or are a physician, therapist, RN, or pharmacist who would like to partner with us, use the form below.
For a quicker response, use the chat feature at the bottom of the page.
Interested in learning more about Digital Therapeutics Technology or AI-driven DTx lifestyle modification?
Send us a message using this contact form, or for faster response, use the chat feature at the base of the page.
Monday – Friday, 6:30 am – 5:30 pm
Not all services are available in all locations. Available locations include: Belgium, France, Germany, Italy, and the USA.
Here are some common questions.
Have a question?
Chances are, you’ll be able to find the answer you need below.
Pharmaceutical Companies Embrace Digital Diabetes DTx Therapeutics with RAVCARE’s Innovative Solutions
In the ever-evolving healthcare landscape, pharmaceutical companies are continuously seeking innovative ways to enhance their treatment offerings. In this pursuit, digital therapeutics (DTx) have emerged as a transformative force, offering a personalized and data-driven approach to complement traditional pharmacotherapy. Leading the charge in this realm is RAVCARE, a pioneer in DTx solutions, empowering pharmaceutical companies to seamlessly integrate DTx into their treatment strategies.
RAVCARE’s comprehensive DTx platform seamlessly integrates with existing pharmaceutical products, providing a holistic approach to patient care. This integration enables seamless data exchange between DTx and pharmacotherapy, fostering a deeper understanding of patient responses and treatment outcomes. By leveraging RAVCARE’s DTx solutions, pharmaceutical companies can enhance patient engagement and adherence through personalized interventions, provide real-time monitoring of patient progress and treatment efficacy, and gather valuable data to inform future drug development and clinical trials,
The integration of RAVCARE’s DTx solutions into pharmaceutical treatment plans offers a multitude of benefits for patients. DTx can provide: – Personalized guidance and support for lifestyle modifications – Remote monitoring and symptom management – Enhanced self-efficacy and empowerment in managing their health conditions
In many jurisdictions, yes. These jurisdictions include Belgium, France, Germany, Italy, and the USA. Many other countries also provide therapeutics as part of the their healthcare system.